Medtronic Completes Acquisition of Covidien for $49.9 Billion
| Printer friendly version
(January 26, 2015) Medtronic announced today that it has finally completed its previously announced acquisition of Covidien. According to the press release provided by Medtronic, the “cash-and-stock transaction is valued at approximately $49.9 billion.”
Regarding the acquisition, Omar Ishrak, chairman and CEO of Medtronic said:
“The culmination of this acquisition marks a significant milestone in our industry, creating a company uniquely positioned to alleviate pain, restore health and extend life for more patients around the world. We can now bring together the extensive and innovative capabilities of both Medtronic and Covidien with an underlying objective to solve healthcare’s biggest challenge – expanding access and improving clinical outcomes, while lowering costs.”
A new page on Medtronic’s website welcomes Covidien to the “new Medtronic” and outlines their future together. It notes, “[t]ogether, Medtronic and Covidien are working to improve healthcare by addressing the needs of more people, in more ways and in more places around the world.”
The previously announced acquisition had been on hold pending approval of the deal by the Irish Supreme Court, which issued earlier. The deal had previously been approved by both the Federal Trade Commission in the United States and the European Union’s European Commission.
According to the Boston Globe, the acquisition is among the largest in the medical device sector.
Related
Mitch Hadley
Mitchell Hadley is an associate in our San Diego office. His practice involves all aspects of patent prosecution.
Prior to joining the firm, Mr. Hadley attended law school at the Brigham Young University, J. Reuben Clark Law School where he graduated magna cum laude and was elected to the Order of the Coif. During law school he served as Lead Note and Comment Editor of the BYU law Review. In 2010, he graduated from Brigham Young University with a B.S. in Mechanical Engineering.
Mr. Hadley joined the firm in 2014 after working as summer associate in the firm's San Diego office during the summer of 2013.
Click here to read full bio View all posts published by Mitch Hadley »
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
Share